Table. Baseline Clinical Features of the 623 Patients With NSCLC Treated With Anti-PD(L)1 Immunotherapy.
| Characteristic | irAEs, No. (%) | P valuea | ||
|---|---|---|---|---|
| None | Single | Multiple | ||
| No. | 417 | 148 | 58 | |
| Age, median (range), y | 66 (58-73) | 65 (60-73) | 65.5 (57-73) | .89 |
| Sex | ||||
| Male | 249 (59.7) | 90 (60.8) | 36 (62.1) | .93 |
| Female | 168 (40.3) | 58 (39.2) | 22 (37.9) | |
| Race | ||||
| African American | 55 (13.2) | 19 (12.8) | 5 (8.6) | .71 |
| White | 323 (77.5) | 112 (75.7) | 45 (77.6) | |
| Asian | 39 (9.4) | 17 (11.5) | 8 (13.8) | |
| Smoking status | ||||
| Ever | 341 (81.8) | 123 (83.1) | 49 (84.5) | <.001 |
| Never | 74 (17.7) | 25 (16.9) | 9 (15.5) | |
| NA | 2 (0.5) | 0 (0.0) | 0 (0.0) | |
| Stage at diagnosis | ||||
| III | 52 (12.5) | 5 (3.4) | 1 (1.7) | <.001 |
| IV | 365 (87.5) | 143 (96.6) | 57 (98.3) | |
| ECOG PS | ||||
| 0/1 | 340 (81.5) | 127 (85.8) | 55 (94.8) | .03 |
| 2 | 77 (18.5) | 21 (14.2) | 3 (5.2) | |
| Histology | ||||
| Adenocarcinoma | 280 (67.1) | 102 (68.9) | 44 (75.9) | .35 |
| Squamous cell | 115 (27.6) | 38 (25.7) | 9 (15.5) | |
| NOS | 22 (5.3) | 8 (5.4) | 5 (8.6) | |
| Treatment received | ||||
| Monotherapy | 341 (81.8) | 135 (91.2) | 51 (87.9) | .02 |
| Combination therapy | 76 (18.2) | 13 (8.8) | 7 (12.1) | |
| +CTLA-4 | 18 (4.3) | 3 (2.0) | 5 (8.6) | .01 |
| +Chemotherapy | 30 (7.2) | 2 (1.4) | 1 (1.7) | |
| +Otherb | 28 (6.7) | 8 (5.4) | 1 (1.7) | |
| Anti–PD-(L)1 type | ||||
| PD-1 | 393 (94.2) | 142 (95.9) | 58 (100) | .14 |
| PD-L1 | 24 (5.8) | 6 (4.1) | 0 (0) | |
| ICI duration, median (range), wk | 10.1 (4.36-21) | 17.1 (6.43-42.9) | 27.9 (9.71-51.4) | <.001 |
| Best treatment response | ||||
| CR, PR, SD | 117 (28.1) | 75 (50.7) | 43 (74.1) | <.001 |
| PD | 234 (56.1) | 50 (33.8) | 12 (20.7) | |
| NA | 66 (15.8) | 23 (15.5) | 3 (5.2) | |
Abbreviations: CR, complete response; CTLA-4, cytotoxic T-lymphocyte-associated antigen 4; ECOG PS, Eastern Cooperative Oncology Group performance status; ICI, immune checkpoint inhibitor; NA, not applicable; NOS, not otherwise specified; PD, progressive disease; PD-(L)1, programmed cell death (ligand) 1; PR, partial response; SD, stable disease.
a
Categorical and continuous variables were compared using χ2 and Kruskal-Wallis tests, respectively.
b
Other: anti-ERBB2, anti-LAG3, anti-TIM3, anti-KIR therapy; azacitidine/etinostat epigenetic priming.